The Schwab Fundamental International Equity ETF (FNDF) provides diversified exposure to large international companies at a lower price-to-earnings ratio (14.07) compared to benchmarks like EFA and the S&P 500. It benefits from strong European earnings growth and offers a 3.03% annual yield, making it attractive for investors seeking value and income abroad. However, FNDF's performance is sensitive to energy sector fluctuations, currency changes, and central bank policies, with risks heightened by its reliance on energy and materials sectors and a strong U.S. dollar. The analyst rates FNDF as a 'buy' based on its valuation, diversification, and yield but advises reconsideration if the ETF falls below its 200-day moving average.
The Schwab Fundamental International Equity ETF (FNDF) is noted for its lower price-to-earnings ratio of 14.07 and a 3.03% annual yield, providing value and income opportunities amid global market dynamics. For readers following US stocks on Pluang, here is the market snapshot as of Oct 23, 2026 19:11 WIB: out of 150 priced stocks, 38 rose and 109 fell. Notable movers include Moderna (MRNA) at USD 193.65 with a 4.43% decline and 71% sell order activity, Verizon Communications (VZ) at USD 43.26 down 4.29% with 63% sell orders, and Xpeng Inc (XPEV) at USD 9.42 up 3.86% with 57% sell orders.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
